Latest breakthroughs in cancer research, treatment, and prevention
602 articles
A pyruvate metabolism enzyme suppresses leucine catabolism to keep mTOR active in liver cancer — and blocking it shrinks tumors in vivo.
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
A bespoke DNA vaccine tailored to individual glioblastoma tumors shows promising immunological activity in one of oncology's hardest challenges.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
MAIT cells appear to provide protective immune surveillance in Lynch syndrome carriers who haven't developed colorectal cancer, suggesting new risk stratification tools.
A comprehensive review in CA Cancer J Clin maps the molecular biology, treatment strategies, and equity gaps in high-grade serous ovarian cancer.
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
A completed NCI trial evaluated advanced imaging and breast duct lavage in women with BRCA1/BRCA2 mutations to improve early cancer detection.
New research reveals how lung cancer subclones develop distinct immune evasion strategies, complicating immunotherapy response.
Memorial Sloan Kettering-led trials produced 11 new FDA-approved cancer therapies in a single year, spanning multiple tumor types.
